Polymyalgia rheumatica has long been neglected, especially when it comes to pharmaceutical development: but why? In 2025, polymyalgia rheumatica should have a broad therapeutic armamentarium analogous to other common inflammatory diseases. Polymyalgia rheumatica is common within major pharmaceutical markets, given its lifetime incidence risk of approximately 2%.1 Despite this, it remains completely underserved by pharmacotherapeutics, with a single therapy registered in major jurisdictions.
The Lancet